Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US3596161097
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00DDY1RK9
FULC
Fulcrum Therapeutics Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Fulcrum Therapeutics Inc
ISIN
US3596161097
TICKER
FULC
MIC
XNAS
REUTERS
FULC.OQ
BLOOMBERG
FULC US
Mo., 05.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 03.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 3, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 03.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 3, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, i...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 02.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 2, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 01.06.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - June 1, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 01.06.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - June 1, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 01.06.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - June 1, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 31.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 31, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 30.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 30, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 29.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 29, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 29.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 29, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 26.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 26, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 26.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 25, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 25, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, i...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 25, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 25, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 25.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 24, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you pur...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 24.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 24, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 24.05.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. New York, New York--(...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 23.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 23, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 22.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 22, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 22.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 22, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Sa., 20.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 20, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc. (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchase...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 19, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 19.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 19, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 18.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 18, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 17, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 17.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 17, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, i...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 16.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 16, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 16.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 15, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 15.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 15, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 12, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 12.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 12, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 11.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 11, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 10, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"), of the important June 27, 2023 lead plaintiff deadline.SO WHAT: If you purchas...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 10, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 10.05.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights. New York, New York--(Newsf...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 09.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 9, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 09.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 8, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360, is...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 8, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mo., 08.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 7, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 5, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Fulcrum Therapeutics Inc., (NASDAQ: FULC) between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Fr., 05.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 5, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 04.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 4, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Mi., 03.05.2023       Fulcrum Therapeutics
US3596161097

Los Angeles, California--(Newsfile Corp. - May 3, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 p...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.05.2023       Fulcrum Therapeutics
US3596161097

Philadelphia, Pennsylvania--(Newsfile Corp. - May 2, 2023) - Berger Montague advises investors that a securities fraud class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum") (NASDAQ: FULC) on behalf of those who purchased Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the "Class Period"...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.05.2023       Fulcrum Therapeutics
US3596161097

Did you lose money on investments in Fulcrum Therapeutics, Inc.? If so, please visit Fulcrum Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.New York, New York--(Newsfile Corp. - May 2, 2023) - Bernstein Liebhard LLP announces that a securities class act...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Di., 02.05.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - May 2, 2023) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Fulcrum Therapeutics, Inc. ("Fulcrum" or "the Company") (NASDAQ: FULC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promul...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
So., 30.04.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - April 30, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC), and certain officers. The class action, filed in the United States District Court for the District of New Jersey, and docketed under 23-cv-02360,...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink
Do., 09.03.2023       Fulcrum Therapeutics
US3596161097

New York, New York--(Newsfile Corp. - March 8, 2023) - Pomerantz LLP is investigating claims on behalf of investors of Fulcrum Therapeutics, Inc. ("Fulcrum" or the "Company") (NASDAQ: FULC). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Fulcrum and...
Zur Nachricht
Fulcrum Therapeutics
Charts & Research Termsheets Terminal
Permalink